<p>在過去三個月中，4 位分析師對 Dianthus Therapeutics（納斯達克股票代碼：DNTH）發佈了評級，呈現出從看漲到看跌的廣泛觀點。</p>
<p>總結他們最近的評估，下面的表格展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>略微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>略微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>在對 12 個月價格目標的評估中，分析師為 Dianthus Therapeutics 提供了見解，給出了 62.25 美元的平均目標，最高預估為 100.00 美元，最低預估為 40.00 美元。當前的平均目標較之前的 54.00 美元提高了 15.28%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1757426464_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1757426464_0.png"/></p>
<h2>解讀分析師評級：更深入的觀察</h2>
<p>通過審視最近的分析師行動，我們獲得了金融專家如何看待 Dianthus Therapeutics 的見解。以下總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>上調</td>
<td>買入</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>上調</td>
<td>超越大盤</td>
<td>$67.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright \u0026 Co.</td>
<td>維持</td>
<td>買入</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>上調</td>
<td>超越大盤</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師對市場條件和公司表現的變化作出反應，頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對 Dianthus Therapeutics 相關最新發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 深入評估，分析師賦予定性值，從 “超越大盤” 到 “表現不佳”。這些評級傳達了對 Dianthus Therapeutics 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 通過獲得見解，分析師提供了對 Dianthus Therapeutics 股票未來價值的估計。這種比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
<p>為了全面瞭解 Dianthus Therapeutics 的市場表現，請將這些分析師評估與重要的財務指標結合起來。保持信息靈通，利用我們的評級表做出明智的決策。</p>
<p>隨時瞭解 Dianthus Therapeutics 的分析師評級。</p>
<p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
<h2>關於 Dianthus Therapeutics</h2>
<p>Dianthus Therapeutics Inc 是一家臨牀階段的生物技術公司，致力於設計和提供具有更高選擇性和效力的新型單克隆抗體，超越現有的補體療法。該公司專注於為患有嚴重自身免疫和炎症疾病的患者開發下一代補體療法。公司由一支經驗豐富的生物技術和製藥高管團隊組成。公司的產品管線包括 DNTH103，一種皮下活性 C1s 抗體。</p>
<h3>關鍵指標：Dianthus Therapeutics 的財務健康狀況</h3>
<p><strong>市值分析：</strong> 該公司的市值水平較低，低於行業平均水平。這表明其相對於同行的規模較小。</p>
<p><strong>收入挑戰：</strong> Dianthus Therapeutics 在過去 3 個月的收入增長面臨困難。截至 2025 年 6 月 30 日，該公司經歷了約 <strong>-89.64%</strong> 的下降。這表明其收入出現了下降。與同行相比，該公司的收入增長落後於行業同行。該公司的增長率低於醫療保健行業同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Dianthus Therapeutics 的淨利潤率低於行業平均水平，表明在維持強勁盈利能力方面可能面臨挑戰。淨利潤率為 <strong>-16388.08%</strong>，該公司可能在有效成本管理方面面臨困難。</p>
<p><strong>股本回報率（ROE）：</strong> Dianthus Therapeutics 的 ROE 低於行業平均水平，表明在有效利用股本方面存在挑戰。ROE 為 <strong>-10.01%</strong>，該公司可能在為股東創造最佳回報方面面臨困難。</p>
<p><strong>資產回報率（ROA）：</strong> Dianthus Therapeutics 的 ROA 低於行業標準，表明在有效利用資產方面存在困難。ROA 為 <strong>-9.38%</strong>，該公司可能在從其資產中提供令人滿意的回報方面面臨挑戰。</p>
<p><strong>債務管理：</strong> Dianthus Therapeutics 的債務與股本比率低於行業平均水平。該比率為 <strong>0.0</strong>，表明該公司較少依賴債務融資，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
<h2>分析師評級的基礎知識</h2>
<p>在銀行和金融系統領域，分析師專注於特定股票或定義行業的報告。他們的工作包括參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈股票的 “分析師評級”。分析師通常每季度評估和評級每隻股票一次。</p>
<p>一些分析師發佈他們對增長預估、收益和收入等指標的預測，以提供額外的評級指導。在使用分析師評級時，重要的是要記住，股票和行業分析師也是人，他們只是向投資者提供他們的意見。</p>
<p><strong>突發：華爾街下一個大動向</strong></p>
<p>Benzinga 的首席分析師剛剛識別出一隻有望實現爆炸性增長的股票。這家低調的公司在重大市場變動中可能會激增 200% 以上。點擊這裏獲取緊急詳情。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

DNTH

<p>分析師最近對 Dianthus Therapeutics（NASDAQ:DNTH）提供了不同的評級，平均 12 個月目標價為 62.25 美元，較之前的目標上漲了 15.28%。主要分析師提高了他們的評級，Guggenheim 設定的目標為 100.00 美元。儘管這些前景積極，但公司面臨着重大的收入挑戰，過去三個月收入下降約-89.64%，淨利潤率為-16388.08%。Dianthus Therapeutics 專注於開發用於嚴重自身免疫疾病的新型單克隆抗體</p>

<p>In the preceding three months, 4 analysts have released ratings for Dianthus Therapeutics (NASDAQ: DNTH), presenting a wide array of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在過去三個月中，4 位分析師對 Dianthus Therapeutics（納斯達克股票代碼：DNTH）發佈了評級，呈現出從看漲到看跌的廣泛觀點。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>總結他們最近的評估，下面的表格展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>略微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>略微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>In the assessment of 12-month price targets, analysts unveil insights for Dianthus Therapeutics, presenting an average target of $62.25, a high estimate of $100.00, and a low estimate of $40.00. This current average has increased by 15.28% from the previous average price target of $54.00.</p>
<div class="lb-trans"><p>在對 12 個月價格目標的評估中，分析師為 Dianthus Therapeutics 提供了見解，給出了 62.25 美元的平均目標，最高預估為 100.00 美元，最低預估為 40.00 美元。當前的平均目標較之前的 54.00 美元提高了 15.28%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1757426464_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2025/1757426464_0.png"/></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<div class="lb-trans"><h2>解讀分析師評級：更深入的觀察</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive Dianthus Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過審視最近的分析師行動，我們獲得了金融專家如何看待 Dianthus Therapeutics 的見解。以下總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>上調</td>
<td>買入</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>上調</td>
<td>超越大盤</td>
<td>$67.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright \u0026 Co.</td>
<td>維持</td>
<td>買入</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>上調</td>
<td>超越大盤</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dianthus Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Dianthus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師對市場條件和公司表現的變化作出反應，頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對 Dianthus Therapeutics 相關最新發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 深入評估，分析師賦予定性值，從 “超越大盤” 到 “表現不佳”。這些評級傳達了對 Dianthus Therapeutics 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 通過獲得見解，分析師提供了對 Dianthus Therapeutics 股票未來價值的估計。這種比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
</div><p>To gain a panoramic view of Dianthus Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了全面瞭解 Dianthus Therapeutics 的市場表現，請將這些分析師評估與重要的財務指標結合起來。保持信息靈通，利用我們的評級表做出明智的決策。</p>
</div><p>Stay up to date on Dianthus Therapeutics analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Dianthus Therapeutics 的分析師評級。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
</div><h2>About Dianthus Therapeutics</h2>
<div class="lb-trans"><h2>關於 Dianthus Therapeutics</h2>
</div><p>Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.</p>
<div class="lb-trans"><p>Dianthus Therapeutics Inc 是一家臨牀階段的生物技術公司，致力於設計和提供具有更高選擇性和效力的新型單克隆抗體，超越現有的補體療法。該公司專注於為患有嚴重自身免疫和炎症疾病的患者開發下一代補體療法。公司由一支經驗豐富的生物技術和製藥高管團隊組成。公司的產品管線包括 DNTH103，一種皮下活性 C1s 抗體。</p>
</div><h3>Key Indicators: Dianthus Therapeutics's Financial Health</h3>
<div class="lb-trans"><h3>關鍵指標：Dianthus Therapeutics 的財務健康狀況</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 該公司的市值水平較低，低於行業平均水平。這表明其相對於同行的規模較小。</p>
</div><p><strong>Revenue Challenges:</strong> Dianthus Therapeutics's revenue growth over 3M faced difficulties. As of 30 June, 2025, the company experienced a decline of approximately <strong>-89.64%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>收入挑戰：</strong> Dianthus Therapeutics 在過去 3 個月的收入增長面臨困難。截至 2025 年 6 月 30 日，該公司經歷了約 <strong>-89.64%</strong> 的下降。這表明其收入出現了下降。與同行相比，該公司的收入增長落後於行業同行。該公司的增長率低於醫療保健行業同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Dianthus Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-16388.08%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Dianthus Therapeutics 的淨利潤率低於行業平均水平，表明在維持強勁盈利能力方面可能面臨挑戰。淨利潤率為 <strong>-16388.08%</strong>，該公司可能在有效成本管理方面面臨困難。</p>
</div><p><strong>Return on Equity (ROE):</strong> Dianthus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-10.01%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Dianthus Therapeutics 的 ROE 低於行業平均水平，表明在有效利用股本方面存在挑戰。ROE 為 <strong>-10.01%</strong>，該公司可能在為股東創造最佳回報方面面臨困難。</p>
</div><p><strong>Return on Assets (ROA):</strong> Dianthus Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-9.38%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Dianthus Therapeutics 的 ROA 低於行業標準，表明在有效利用資產方面存在困難。ROA 為 <strong>-9.38%</strong>，該公司可能在從其資產中提供令人滿意的回報方面面臨挑戰。</p>
</div><p><strong>Debt Management:</strong> Dianthus Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.0</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Dianthus Therapeutics 的債務與股本比率低於行業平均水平。該比率為 <strong>0.0</strong>，表明該公司較少依賴債務融資，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析師評級的基礎知識</h2>
</div><p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>在銀行和金融系統領域，分析師專注於特定股票或定義行業的報告。他們的工作包括參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈股票的 “分析師評級”。分析師通常每季度評估和評級每隻股票一次。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析師發佈他們對增長預估、收益和收入等指標的預測，以提供額外的評級指導。在使用分析師評級時，重要的是要記住，股票和行業分析師也是人，他們只是向投資者提供他們的意見。</p>
</div><p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<div class="lb-trans"><p><strong>突發：華爾街下一個大動向</strong></p>
</div><p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.</p>
<div class="lb-trans"><p>Benzinga 的首席分析師剛剛識別出一隻有望實現爆炸性增長的股票。這家低調的公司在重大市場變動中可能會激增 200% 以上。點擊這裏獲取緊急詳情。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

分析師對 Dianthus Therapeutics 未來發展的預期